Monotherapy Dose Finding With BI 847325 in Solid Tumours

• ClinicalTrials.gov Identifier: NCT01324830
• Recruitment Status: Completed
• First Posted: March 29, 2011
• Results First Posted: December 21, 2018
• Last Update Posted: December 21, 2018
• Sponsor: Boehringer Ingelheim
• Information provided by (Responsible Party): Boehringer Ingelheim

Study Description

Brief Summary:

The aim of the Phase Ia (dose escalation) part of this trial is to assess the maximum tolerated dose (MTD) of BI 847325 administered at escalating doses in 2 treatment arms. In the Phase Ib expansion part of the trial, the aim is to further evaluate the safety profile of BI 847325 at the recommended dose and schedule and to assess target modulation and the potential antitumour efficacy in patients with selected tumour types.

Condition or disease	Intervention/treatment	Phase
Neoplasms	Drug: day 1 to day 5; Drug: day 1 to day 14	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 69 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open Label Phase Ia/Ib Study of Two Dosing Schedules of BI 847325, Orally Administered Once a Day in Patients With Advanced Solid Tumours, With Repeated Cyclic Administration in Patients With Clinical Benefit
• Actual Study Start Date: April 15, 2011
• Actual Primary Completion Date: June 6, 2013
• Actual Study Completion Date: October 10, 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: arm A; 14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles	Drug: day 1 to day 14; low to high dose
Experimental: arm B; 5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week	Drug: day 1 to day 5; low to high dose

Outcome Measures

Primary Outcome Measures :

1. Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study [ Time Frame: 3 weeks ]

   Occurrence of dose limiting toxicity (DLT) during the first treatment cycle for the treatment Schedules A and B.

   Some patients excluded from Treated Set (TS) as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients.

Secondary Outcome Measures :

1. Best Overall Response [ Time Frame: From the start of treatment until the last evaluable assessment. The data cut-off date is 29-Nov-2013 ]
   Best overall response was the best response a patient experienced during their time on study from the start of treatment until: disease progression, the last evaluable assessment in the absence of progression, or the start of subsequent anti-cancer therapy. Death was not considered as progressive disease when determining best overall response; patients who died prior to an evaluable imaging assessment were reported as not evaluable. Some patients were excluded from TS as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients.
2. Objective Response [ Time Frame: From the start of treatment and the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013. ]

   Objective response was a best overall response of complete or partial response, recorded between the start of treatment and the earliest of disease progression, death, or the end of treatment.

   Some patients excluded from TS as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients.

3. Disease Control [ Time Frame: From the start of treatment to the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013. ]
   Disease control was a best overall response of complete response, partial response or stable disease, recorded between the start of treatment and the earliest of disease progression, death, or the end of treatment. Some patients excluded from TS as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

1. Patients with a histologically or cytologically confirmed diagnosis of an advanced unresectable and/or metastatic solid tumour, and who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not amenable to standard therapies.
2. Age 18 years and older
3. Written informed consent consistent with International conference on harmonization - Good clinical practice (ICH-GCP) and local legislation
4. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
5. Recovery of therapy-related toxicities from previous anti-tumour therapies to Common Terminology Criteria for Adverse Events (CTCAE) = grade 1 (with the exception of alopecia).
6. Written informed consent to the use of archival tumour sample for determination of the BRAF/Tat sarcoma viral oncogene homolog (RAS) mutational status.
7. Life expectancy of at least 12 weeks.

8. In escalation phase, when pharmacokinetic (PK) close to predicted Cmax or when signs of progressive disease (PD) modulation present, optional tumour biopsies (at same timepoints as in expansion phase) for the patients who consented to it.

   In addition, all patients included in the expansion phase (part Ib) must:

9. have been diagnosed with one of the following tumours: melanoma, colorectal carcinoma, Non Small Cell Lung Cancer (NSCLC) or exocrine pancreas adenocarcinoma, and have been shown on their archival tumour sample to have KRAS or BRAF mutation.
10. have a measurable disease.
11. have documented/proven progressive disease within the last 6 months, according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria

11. have a tumour lesion accessible for biopsies (pre- and post-treatment): this is mandatory for patients with colorectal carcinoma or melanoma, optional for patients with NSCLC or exocrine pancreas adenocarcinoma.

Exclusion criteria:

1. Inability to swallow tablets.
2. Additional other serious illness , concomitant non-oncological disease (e.g. active infectious disease or known chronic Hepatitis B/Hepatitis C infection and HIV), or ongoing toxicity from prior therapies considered by the investigator to potentially compromise patient's safety in this trial.
3. Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the last 28 days.
4. Second malignancy currently requiring another anti-cancer therapy.
5. Absolute neutrophil count less than 1500/mm3.
6. Platelet count less than 100 000/mm3.
7. Bilirubin greater than 1.5 mg/dL (>26 µmol/L, Système international (SI) unit equivalent) (except known Gilbert's syndrome).
8. Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases, greater than five times the upper limit of normal).
9. Serum creatinine greater than 1.5 mg/dL (>132 µmol/L, SI unit equivalent).
10. Previous episode of QT prolongation due to a medication which, as a result of it, had to be discontinued; or long QT syndrome; or corrected QT interval (QTc) with Fridericia's correction >480 msec on screening ECG.
11. Pregnancy or breastfeeding.
12. Women or men who are sexually active and unwilling to use a medically acceptable method of contraception.
13. Treatment with other investigational drugs or participation in another clinical interventional trial within the past four weeks before start of therapy or concomitant with this trial.
14. Systemic anti-cancer therapy or radiotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to Luteinizing hormone-releasing hormone (LHRH) agonists, steroids and bisphosphonates.
15. Patients unable to comply with the protocol.
16. Active alcohol or drug abuse.
17. history or presence of cardiovascular abnormalities deemed clinically relevant by the investigator. Myocardial infarction within 6 months prior to study.
18. Cardiac left ventricular ejection fraction <50% or less than institutional lower limit of normal by Multiple Gated Acquisition scan (MUGA) or echocardiography

Contacts and Locations

Locations

Belgium

1287.1.3201 Boehringer Ingelheim Investigational Site

Bruxelles, Belgium

1287.1.3202 Boehringer Ingelheim Investigational Site

Leuven, Belgium

Sponsors and Collaborators

Boehringer Ingelheim

Investigators

• Study Chair: Boehringer Ingelheim; Boehringer Ingelheim

More Information

Additional Information:

Related Info 

• Responsible Party: Boehringer Ingelheim
• ClinicalTrials.gov Identifier: NCT01324830
• Other Study ID Numbers: 1287.1; 2010-023832-18 ( EudraCT Number: EudraCT )
• First Posted: March 29, 2011
• Results First Posted: December 21, 2018
• Last Update Posted: December 21, 2018
• Last Verified: June 2018